Novartis Challenge To India Patent Law Put Off To 11 September

Print This Post Print This Post

The Supreme Court of India today did not get to an agenda item involving a challenge to India’s patent law by Swiss pharmaceutical company Novartis, and it is now scheduled to come up on 11 September. The case is considered to have potential widespread impact on the production of lower priced generic medicines.

Since 2005, Novartis has been trying to contest a clause, Section 3(d), of India’s 2005 patent law, intended to prevent patenting of pharmaceutical variations that are not true innovations. The focus of the case is a cancer drug known as Glivec (or Gleevec), which were being marketed before 2005.

An Intellectual Property Watch background story is available here.

Creative Commons License"Novartis Challenge To India Patent Law Put Off To 11 September" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Leave a Reply